Tái phát bệnh bạch cầu cấp tính ở trẻ em sau khi cấy ghép tế bào gốc đồng loại cho thấy sự đa dạng cao, động lực clone, áp lực chọn lọc và những mục tiêu có thể điều trị

Pui, 2015, Childhood acute lymphoblastic leukemia: progress through collaboration, J Clin Oncol, 33, 2938, 10.1200/JCO.2014.59.1636 Eckert, 2013, Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group, J Clin Oncol, 31, 2736, 10.1200/JCO.2012.48.5680 Tallen, 2010, Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90, J Clin Oncol, 28, 2339, 10.1200/JCO.2009.25.1983 Peters, 2015, Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial, J Clin Oncol, 33, 1265, 10.1200/JCO.2014.58.9747 Kato, 2012, Second allogeneic hematopoietic SCT for relapsed ALL in children, Bone Marrow Transplant, 47, 1307, 10.1038/bmt.2012.29 Kuhlen, 2018, Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial, Br J Haematol, 180, 82, 10.1111/bjh.14965 Schlegel, 2014, Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab, Haematologica, 99, 1212, 10.3324/haematol.2013.100073 Kantarjian, 2016, Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia, N Engl J Med, 375, 740, 10.1056/NEJMoa1509277 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Bajwa, 2013, Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies, Bone Marrow Transplant, 48, 661, 10.1038/bmt.2012.209 Xiao, 2016, Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation, Oncotarget, 7, 2696, 10.18632/oncotarget.6259 Gröbner, 2018, The landscape of genomic alterations across childhood cancers [published correction appears in Nature. 2018;559(7714):E10], Nature, 555, 321, 10.1038/nature25480 Ma, 2018, Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours, Nature, 555, 371, 10.1038/nature25795 Ding, 2017, Mutational landscape of pediatric acute lymphoblastic leukemia [published correction appears in Cancer Res. 2017;77(8):2174], Cancer Res, 77, 390, 10.1158/0008-5472.CAN-16-1303 Paulsson, 2015, The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia, Nat Genet, 47, 672, 10.1038/ng.3301 Liu, 2017, The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia, Nat Genet, 49, 1211, 10.1038/ng.3909 Meyer, 2013, Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia, Nat Genet, 45, 290, 10.1038/ng.2558 Tzoneva, 2013, Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL, Nat Med, 19, 368, 10.1038/nm.3078 Oshima, 2016, Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia, Proc Natl Acad Sci USA, 113, 11306, 10.1073/pnas.1608420113 Ma, 2015, Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia, Nat Commun, 6, 6604, 10.1038/ncomms7604 Hoell, 2014, Constitutional mismatch repair-deficiency and whole-exome sequencing as the means of the rapid detection of the causative MSH6 defect, Klin Padiatr, 226, 357 Li, 2010, Fast and accurate long-read alignment with Burrows-Wheeler transform, Bioinformatics, 26, 589, 10.1093/bioinformatics/btp698 Li, 2009, The sequence alignment/map format and SAMtools, Bioinformatics, 25, 2078, 10.1093/bioinformatics/btp352 Duraku, 2013, Re-innervation patterns by peptidergic Substance-P, non-peptidergic P2X3, and myelinated NF-200 nerve fibers in epidermis and dermis of rats with neuropathic pain, Exp Neurol, 241, 13, 10.1016/j.expneurol.2012.11.029 Gomes, 2010, Variations in the quality and costs of end-of-life care, preferences and palliative outcomes for cancer patients by place of death: the QUALYCARE study, BMC Cancer, 10, 400, 10.1186/1471-2407-10-400 DePristo, 2011, A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nat Genet, 43, 491, 10.1038/ng.806 McLaren, 2010, Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, 26, 2069, 10.1093/bioinformatics/btq330 Adzhubei, 2010, A method and server for predicting damaging missense mutations, Nat Methods, 7, 248, 10.1038/nmeth0410-248 Kumar, 2009, Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm, Nat Protoc, 4, 1073, 10.1038/nprot.2009.86 Ester, 1996 Hahsler, 2018 Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, 31, 213, 10.1038/nbt.2514 Koboldt, 2012, VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing, Genome Res, 22, 568, 10.1101/gr.129684.111 Bodini, 2015, The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations, Blood, 125, 600, 10.1182/blood-2014-05-576157 Worst, 2016, Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study, Eur J Cancer, 65, 91, 10.1016/j.ejca.2016.06.009 Bykov, 2016, Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy, Front Oncol, 6, 21, 10.3389/fonc.2016.00021 Deneberg, 2016, An open-label phase I dose-finding study of APR-246 in hematological malignancies, Blood Cancer J, 6, e447, 10.1038/bcj.2016.60 Lehmann, 2012, Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer, J Clin Oncol, 30, 3633, 10.1200/JCO.2011.40.7783 Wiman, 2010, Pharmacological reactivation of mutant p53: from protein structure to the cancer patient, Oncogene, 29, 4245, 10.1038/onc.2010.188 Demir, Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia [published online ahead of print 9 May 2019], Haematologica Mullighan, 2007, Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia, Nature, 446, 758, 10.1038/nature05690 Fischer, 2015, Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options, Nat Genet, 47, 1020, 10.1038/ng.3362 Chen, 2015, Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients, Leuk Res, 39, 990, 10.1016/j.leukres.2015.06.005 Kunz, 2015, Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation, Haematologica, 100, 1442, 10.3324/haematol.2015.129692 Mullighan, 2008, Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, Science, 322, 1377, 10.1126/science.1164266 Tzoneva, 2018, Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia, Nature, 553, 511, 10.1038/nature25186 Qian, 2018, TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children, J Clin Oncol, 36, 591, 10.1200/JCO.2017.75.5215 Forero-Castro, 2017, Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia, Br J Cancer, 117, 256, 10.1038/bjc.2017.152 Hof, 2017, NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia, Haematologica, 102, e249, 10.3324/haematol.2016.157792 Hof, 2011, Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia, J Clin Oncol, 29, 3185, 10.1200/JCO.2011.34.8144 Comeaux, 2017, TP53 mutations in hypodiploid acute lymphoblastic leukemia, Cold Spring Harb Perspect Med, 7, a026286, 10.1101/cshperspect.a026286 Chen, 2018, Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53, Leukemia, 32, 850, 10.1038/leu.2017.325 Borthakur, 2016, Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies, Cancer, 122, 1871, 10.1002/cncr.29986 Kerstjens, 2018, Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo, Haematologica, 103, e147, 10.3324/haematol.2017.174060 Irving, 2014, Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition, Blood, 124, 3420, 10.1182/blood-2014-04-531871 Alexandrov, 2013, Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258], Nature, 500, 415, 10.1038/nature12477 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Christopher, 2018, Immune escape of relapsed AML cells after allogeneic transplantation, N Engl J Med, 379, 2330, 10.1056/NEJMoa1808777